169 related articles for article (PubMed ID: 23379777)
1. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.
Lin CJ; Zimmerman RK; Smith KJ
Am J Manag Care; 2013 Jan; 19(1):e30-7. PubMed ID: 23379777
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.
Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE
Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.
Smith KJ; Zimmerman RK; Nowalk MP; Lin CJ
J Am Geriatr Soc; 2017 Apr; 65(4):763-768. PubMed ID: 28024090
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.
Smith KJ; Lee BY; Nowalk MP; Raymund M; Zimmerman RK
Vaccine; 2010 Nov; 28(48):7620-5. PubMed ID: 20887828
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
Hoshi SL; Kondo M; Okubo I
PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
You JH; Wong WC; Ip M; Lee NL; Ho SC
J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic.
Smith KJ; Raymund M; Nowalk MP; Roberts MS; Zimmerman RK
Am J Manag Care; 2010 Mar; 16(3):200-6. PubMed ID: 20225915
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of long-term care facilities associated with standing order programs to deliver influenza and pneumococcal vaccinations to residents in 13 states.
Shefer A; McKibben L; Bardenheier B; Bratzler D; Roberts H
J Am Med Dir Assoc; 2005; 6(2):97-104. PubMed ID: 15871883
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia.
Lara C; De Graeve D; Franco F
Value Health Reg Issues; 2018 Dec; 17():21-31. PubMed ID: 29626706
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.
Wateska AR; Nowalk MP; Zimmerman RK; Smith KJ; Lin CJ
BMC Infect Dis; 2018 Jan; 18(1):52. PubMed ID: 29370768
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis.
Michaelidis CI; Zimmerman RK; Nowalk MP; Smith KJ
Value Health; 2013; 16(2):311-7. PubMed ID: 23538183
[TBL] [Abstract][Full Text] [Related]
12. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
Brydak L; Roiz J; Faivre P; Reygrobellet C
Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
Altawalbeh SM; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Value Health; 2024 Jun; 27(6):721-729. PubMed ID: 38462225
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.
Sisk JE; Whang W; Butler JC; Sneller VP; Whitney CG
Ann Intern Med; 2003 Jun; 138(12):960-8. PubMed ID: 12809452
[TBL] [Abstract][Full Text] [Related]
16. Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Am J Prev Med; 2020 Apr; 58(4):487-495. PubMed ID: 32001052
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China.
Chen D; Ye Z; Pi Z; Mizukami S; Aoyagi K; Jiang Y
Vaccine; 2021 Apr; 39(16):2237-2245. PubMed ID: 33757667
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a toolkit to introduce standing orders for influenza and pneumococcal vaccination in adults: a multimodal pilot project.
Nowalk MP; Nutini J; Raymund M; Ahmed F; Albert SM; Zimmerman RK
Vaccine; 2012 Sep; 30(41):5978-82. PubMed ID: 22835736
[TBL] [Abstract][Full Text] [Related]
20. Standing orders program of pneumococcal vaccination for hospitalized elderly patients in Hong Kong: A cost-effectiveness analysis.
Xing N; Cheung WY; Jiang M; You JHS
Am J Infect Control; 2019 Nov; 47(11):1302-1308. PubMed ID: 31266663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
